Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line.

Van Der Steen N, Leonetti A, Keller K, Dekker H, Funel N, Lardon F, Ruijtenbeek R, Tiseo M, Rolfo C, Pauwels P, Peters GJ, Giovannetti E.

Biochem Pharmacol. 2019 Aug;166:128-138. doi: 10.1016/j.bcp.2019.05.014. Epub 2019 May 10.

PMID:
31078602
2.

Study of cross talk between phosphatases and OGA on a ZO-3-derived peptide.

Sharif S, Shi J, Ruijtenbeek R, Pieters RJ.

Amino Acids. 2019 Apr;51(4):739-743. doi: 10.1007/s00726-019-02699-1. Epub 2019 Feb 6.

PMID:
30725225
3.

Drug-induced aneuploidy and polyploidy is a mechanism of disease relapse in MYC/BCL2-addicted diffuse large B-cell lymphoma.

Islam S, Paek AL, Hammer M, Rangarajan S, Ruijtenbeek R, Cooke L, Weterings E, Mahadevan D.

Oncotarget. 2018 Nov 13;9(89):35875-35890. doi: 10.18632/oncotarget.26251. eCollection 2018 Nov 13.

4.

Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.

Sawada T, Hilhorst R, Rangarajan S, Yoshida M, Tanabe Y, Tamura K, Kinoshita T, Shimoyama T, van Beuningen R, Ruijtenbeek R, Tsuda H, Koizumi F.

Oncotarget. 2018 Sep 28;9(76):34229-34239. doi: 10.18632/oncotarget.26026. eCollection 2018 Sep 28.

5.

Inhibition of O-GlcNAc transferase (OGT) by peptidic hybrids.

Zhang H, Tomašič T, Shi J, Weiss M, Ruijtenbeek R, Anderluh M, Pieters RJ.

Medchemcomm. 2018 Apr 18;9(5):883-887. doi: 10.1039/c8md00115d. eCollection 2018 May 1.

6.

Profiling of 3696 Nuclear Receptor-Coregulator Interactions: A Resource for Biological and Clinical Discovery.

Broekema MF, Hollman DAA, Koppen A, van den Ham HJ, Melchers D, Pijnenburg D, Ruijtenbeek R, van Mil SWC, Houtman R, Kalkhoven E.

Endocrinology. 2018 Jun 1;159(6):2397-2407. doi: 10.1210/en.2018-00149.

PMID:
29718163
7.

Demystifying O-GlcNAcylation: hints from peptide substrates.

Shi J, Ruijtenbeek R, Pieters RJ.

Glycobiology. 2018 Nov 1;28(11):814-824. doi: 10.1093/glycob/cwy031. Review.

PMID:
29635275
8.

Peptide microarray analysis of the cross-talk between O-GlcNAcylation and tyrosine phosphorylation.

Shi J, Tomašič T, Sharif S, Brouwer AJ, Anderluh M, Ruijtenbeek R, Pieters RJ.

FEBS Lett. 2017 Jul;591(13):1872-1883. doi: 10.1002/1873-3468.12708. Epub 2017 Jun 27.

9.

Measuring O-GlcNAc cleavage by OGA and cell lysates on a peptide microarray.

Sharif S, Shi J, Bourakba M, Ruijtenbeek R, Pieters RJ.

Anal Biochem. 2017 Sep 1;532:12-18. doi: 10.1016/j.ab.2017.05.027. Epub 2017 May 29.

10.

Cetuximab Prevents Methotrexate-Induced Cytotoxicity in Vitro through Epidermal Growth Factor Dependent Regulation of Renal Drug Transporters.

Caetano-Pinto P, Jamalpoor A, Ham J, Goumenou A, Mommersteeg M, Pijnenburg D, Ruijtenbeek R, Sanchez-Romero N, van Zelst B, Heil SG, Jansen J, Wilmer MJ, van Herpen CML, Masereeuw R.

Mol Pharm. 2017 Jun 5;14(6):2147-2157. doi: 10.1021/acs.molpharmaceut.7b00308. Epub 2017 May 24.

11.

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells.

Steen NV, Potze L, Giovannetti E, Cavazzoni A, Ruijtenbeek R, Rolfo C, Pauwels P, Peters GJ.

Am J Cancer Res. 2017 Apr 1;7(4):816-830. eCollection 2017.

12.

Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.

van der Zanden LFM, Vermeulen SH, Oskarsdottir A, Maurits JSF, Diekstra MHM, Ambert V, Cambon-Thomsen A, Castellano D, Fritsch A, Garcia Donas J, Guarch Troyas R, Guchelaar HJ, Hartmann A, Hulsbergen-van de Kaa C, Jaehde U, Junker K, Martinez-Cardus A, Masson G, Oosterwijk-Wakka J, Radu MT, Rafnar T, Rodriguez-Antona C, Roessler M, Ruijtenbeek R, Stefansson K, Warren A, Wessels L, Eisen T, Kiemeney LALM, Oosterwijk E.

Urol Oncol. 2017 Aug;35(8):529.e9-529.e16. doi: 10.1016/j.urolonc.2017.03.009. Epub 2017 Apr 3.

13.

Peptide Microarrays for Real-Time Kinetic Profiling of Tyrosine Phosphatase Activity of Recombinant Phosphatases and Phosphatases in Lysates of Cells or Tissue Samples.

Hovestad-Bijl L, van Ameijde J, Pijnenburg D, Hilhorst R, Liskamp R, Ruijtenbeek R.

Methods Mol Biol. 2016;1447:67-78. doi: 10.1007/978-1-4939-3746-2_4.

PMID:
27514800
14.

Activity Based High-Throughput Screening for Novel O-GlcNAc Transferase Substrates Using a Dynamic Peptide Microarray.

Shi J, Sharif S, Ruijtenbeek R, Pieters RJ.

PLoS One. 2016 Mar 9;11(3):e0151085. doi: 10.1371/journal.pone.0151085. eCollection 2016.

15.

Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.

Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijtenbeek R, Wosikowski K, Peters GJ.

Curr Drug Targets. 2014;15(14):1312-21.

PMID:
25382189
16.

Cofactor profiling of the glucocorticoid receptor from a cellular environment.

Desmet SJ, Dejager L, Clarisse D, Thommis J, Melchers D, Bastiaensen N, Ruijtenbeek R, Beck IM, Libert C, Houtman R, Meijer OC, De Bosscher K.

Methods Mol Biol. 2014;1204:83-94. doi: 10.1007/978-1-4939-1346-6_8.

PMID:
25182763
17.

The JH2 domain and SH2-JH2 linker regulate JAK2 activity: A detailed kinetic analysis of wild type and V617F mutant kinase domains.

Sanz Sanz A, Niranjan Y, Hammarén H, Ungureanu D, Ruijtenbeek R, Touw IP, Silvennoinen O, Hilhorst R.

Biochim Biophys Acta. 2014 Oct;1844(10):1835-41. doi: 10.1016/j.bbapap.2014.07.003. Epub 2014 Aug 7.

PMID:
25107665
18.

Azide-alkyne cycloaddition affording enzymatically tunable bisubstrate based inhibitors of histone acetyltransferase PCAF.

van Ameijde J, Zwiebel AP, Ruijtenbeek R, Liskamp RM.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):113-6. doi: 10.1016/j.bmcl.2013.11.060. Epub 2013 Dec 4.

PMID:
24345448
19.

A versatile spectrophotometric protein tyrosine phosphatase assay based on 3-nitrophosphotyrosine containing substrates.

van Ameijde J, Overvoorde J, Knapp S, den Hertog J, Ruijtenbeek R, Liskamp RM.

Anal Biochem. 2014 Mar 1;448:9-13. doi: 10.1016/j.ab.2013.11.023. Epub 2013 Dec 3.

PMID:
24309020
20.

Cell-penetrating bisubstrate-based protein kinase C inhibitors.

van Wandelen LT, van Ameijde J, Ismail-Ali AF, van Ufford HC, Vijftigschild LA, Beekman JM, Martin NI, Ruijtenbeek R, Liskamp RM.

ACS Chem Biol. 2013 Jul 19;8(7):1479-87. doi: 10.1021/cb300709g. Epub 2013 May 8.

PMID:
23621550
21.

Peptide microarrays for profiling of serine/threonine kinase activity of recombinant kinases and lysates of cells and tissue samples.

Hilhorst R, Houkes L, Mommersteeg M, Musch J, van den Berg A, Ruijtenbeek R.

Methods Mol Biol. 2013;977:259-71. doi: 10.1007/978-1-62703-284-1_21.

PMID:
23436369
22.

Development of a microarray detection method for galectin cancer proteins based on ligand binding.

van Hattum H, Martin NI, Ruijtenbeek R, Pieters RJ.

Anal Biochem. 2013 Mar 1;434(1):99-104. doi: 10.1016/j.ab.2012.11.003. Epub 2012 Nov 10.

PMID:
23149235
23.

Functional assay for shiga-like toxin via detection by antibody capture and multivalent galabiose binding.

van Hattum H, van der Zwaluw K, Visser GM, van Putten J, Ruijtenbeek R, Pieters RJ.

Bioorg Med Chem Lett. 2012 Dec 15;22(24):7448-50. doi: 10.1016/j.bmcl.2012.10.053. Epub 2012 Oct 17.

PMID:
23142616
24.

Directed modulation of protein kinase C isozyme selectivity with bisubstrate-based inhibitors.

van Wandelen LT, van Ameijde J, Mady AS, Wammes AE, Bode A, Poot AJ, Ruijtenbeek R, Liskamp RM.

ChemMedChem. 2012 Dec;7(12):2113-21. doi: 10.1002/cmdc.201200349. Epub 2012 Nov 8.

PMID:
23139239
25.

Kinomic profiling approach identifies Trk as a novel radiation modulator.

Jarboe JS, Jaboin JJ, Anderson JC, Nowsheen S, Stanley JA, Naji F, Ruijtenbeek R, Tu T, Hallahan DE, Yang ES, Bonner JA, Willey CD.

Radiother Oncol. 2012 Jun;103(3):380-7. doi: 10.1016/j.radonc.2012.03.014. Epub 2012 May 5.

26.

Protein kinase activity profiling of postmortem human brain tissue.

Hoozemans JJ, Hilhorst R, Ruijtenbeek R, Rozemuller AJ, van der Vies SM.

Neurodegener Dis. 2012;10(1-4):46-8. doi: 10.1159/000335914. Epub 2012 Feb 16.

PMID:
22343098
27.

Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen.

Houtman R, de Leeuw R, Rondaij M, Melchers D, Verwoerd D, Ruijtenbeek R, Martens JW, Neefjes J, Michalides R.

Mol Cancer Ther. 2012 Apr;11(4):805-16. doi: 10.1158/1535-7163.MCT-11-0855. Epub 2012 Feb 7.

28.

The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor.

Tournoij E, Koekman CA, Du VX, Roest M, Ruijtenbeek R, Moll FL, Akkerman JW.

Platelets. 2012;23(8):617-25. doi: 10.3109/09537104.2011.645924. Epub 2012 Jan 24.

PMID:
22273509
29.

Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.

Sanz A, Ungureanu D, Pekkala T, Ruijtenbeek R, Touw IP, Hilhorst R, Silvennoinen O.

PLoS One. 2011 Apr 18;6(4):e18522. doi: 10.1371/journal.pone.0018522.

30.

Identification of new possible targets for leukemia treatment by kinase activity profiling.

Ter Elst A, Diks SH, Kampen KR, Hoogerbrugge PM, Ruijtenbeek R, Boender PJ, Sikkema AH, Scherpen FJ, Kamps WA, Peppelenbosch MP, de Bont ES.

Leuk Lymphoma. 2011 Jan;52(1):122-30. doi: 10.3109/10428194.2010.535181. Epub 2010 Dec 6.

PMID:
21133721
31.

Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.

Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH.

Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):555-62. doi: 10.1016/j.ijrobp.2010.04.036. Epub 2010 Aug 2.

PMID:
20675069
32.

Rapid screening of lectins for multivalency effects with a glycodendrimer microarray.

Parera Pera N, Branderhorst HM, Kooij R, Maierhofer C, van der Kaaden M, Liskamp RM, Wittmann V, Ruijtenbeek R, Pieters RJ.

Chembiochem. 2010 Sep 3;11(13):1896-904. doi: 10.1002/cbic.201000340.

PMID:
20672284
33.

Preparation of novel alkylated arginine derivatives suitable for click-cycloaddition chemistry and their incorporation into pseudosubstrate- and bisubstrate-based kinase inhibitors.

van Ameijde J, Poot AJ, van Wandelen LT, Wammes AE, Ruijtenbeek R, Rijkers DT, Liskamp RM.

Org Biomol Chem. 2010 Apr 7;8(7):1629-39. doi: 10.1039/b922928k. Epub 2010 Feb 4.

PMID:
20237675
34.

Development of selective bisubstrate-based inhibitors against protein kinase C (PKC) isozymes by using dynamic peptide microarrays.

Poot AJ, van Ameijde J, Slijper M, van den Berg A, Hilhorst R, Ruijtenbeek R, Rijkers DT, Liskamp RM.

Chembiochem. 2009 Aug 17;10(12):2042-51. doi: 10.1002/cbic.200900199.

PMID:
19618415
35.

Nuclear receptor-coregulator interaction profiling identifies TRIP3 as a novel peroxisome proliferator-activated receptor gamma cofactor.

Koppen A, Houtman R, Pijnenburg D, Jeninga EH, Ruijtenbeek R, Kalkhoven E.

Mol Cell Proteomics. 2009 Oct;8(10):2212-26. doi: 10.1074/mcp.M900209-MCP200. Epub 2009 Jul 10.

36.

Kinome profiling in pediatric brain tumors as a new approach for target discovery.

Sikkema AH, Diks SH, den Dunnen WF, ter Elst A, Scherpen FJ, Hoving EW, Ruijtenbeek R, Boender PJ, de Wijn R, Kamps WA, Peppelenbosch MP, de Bont ES.

Cancer Res. 2009 Jul 15;69(14):5987-95. doi: 10.1158/0008-5472.CAN-08-3660. Epub 2009 Jun 30.

37.

Peptide microarrays for detailed, high-throughput substrate identification, kinetic characterization, and inhibition studies on protein kinase A.

Hilhorst R, Houkes L, van den Berg A, Ruijtenbeek R.

Anal Biochem. 2009 Apr 15;387(2):150-61. doi: 10.1016/j.ab.2009.01.022. Epub 2009 Jan 21.

PMID:
19344656
38.

Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling.

Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH.

Clin Exp Metastasis. 2009;26(5):485-96. doi: 10.1007/s10585-009-9248-9. Epub 2009 Mar 18.

PMID:
19294521
39.

Multivalent carbohydrate recognition on a glycodendrimer-functionalized flow-through chip.

Branderhorst HM, Ruijtenbeek R, Liskamp RM, Pieters RJ.

Chembiochem. 2008 Jul 21;9(11):1836-44. doi: 10.1002/cbic.200800195.

PMID:
18604837
40.

Endogenous phosphotyrosine signaling in zebrafish embryos.

Lemeer S, Ruijtenbeek R, Pinkse MW, Jopling C, Heck AJ, den Hertog J, Slijper M.

Mol Cell Proteomics. 2007 Dec;6(12):2088-99. Epub 2007 Aug 14.

41.

Protein-tyrosine kinase activity profiling in knock down zebrafish embryos.

Lemeer S, Jopling C, Naji F, Ruijtenbeek R, Slijper M, Heck AJ, den Hertog J.

PLoS One. 2007 Jul 4;2(7):e581.

42.

Replacement of the intervening amino acid sequence of a Syk-binding diphosphopeptide by a nonpeptide spacer with preservation of high affinity.

Dekker FJ, de Mol NJ, van Ameijde J, Fischer MJ, Ruijtenbeek R, Redegeld FA, Liskamp RM.

Chembiochem. 2002 Mar 1;3(2-3):238-42. No abstract available.

PMID:
11921404
43.

Peptoid - peptide hybrids that bind Syk SH2 domains involved in signal transduction.

Ruijtenbeek R, Kruijtzer JA, van de Wiel W, Fischer MJ, Flück M, Redegeld FA, Liskamp RM, Nijkamp FP.

Chembiochem. 2001 Mar 2;2(3):171-9.

PMID:
11828442
44.

Characterization of a phosphorylated peptide and peptoid and peptoid-peptide hybrids by mass spectrometry.

Ruijtenbeek R, Versluis C, Heck AJ, Redegeld FA, Nijkamp FP, Liskamp RM.

J Mass Spectrom. 2002 Jan;37(1):47-55.

PMID:
11813310

Supplemental Content

Loading ...
Support Center